Compare Johnson & Johnson (JNJ) vs Workiva Inc (WK) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Workiva (WK) trades at $57.19, showing minimal daily movement with a 0.02% gain. The stock maintains a bullish technical outlook with strong analyst support (88.9% buy ratings) and a $71 consensus price target. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.77 surpassing the $0.66 estimate. Revenue growth continues with 2026 projections showing $926 million and a return to profitability at 1.53% net margin.

The outlook remains positive given Workiva's dominant market position in compliance software and AI-powered platform growth. Key risks include high valuation multiples (P/E 238.25) and competitive pressures in the enterprise software space. The stock offers 24% upside to consensus targets but requires monitoring of execution against elevated expectations.